                                                  6
         Pharmaceutical       hormone      intermediates     11-ketone-16a,      17a-epoxy
   progesterone synthesis method
         Abstract
 5
         The   present  invention    discloses   pharmaceutical   hormone     intermediates
   11-ketone-16a, 17a-epoxy progesterone synthesis method, comprises the following
   steps:   2-bromine-ila-hydroxy-14-amino-16a,        17a-epoxy   progesterone,    sodium
   sulfate solution were added to the reaction vessel, controlled the stirring speed,
10 controlled the temperature of the solution, reacted; added furan carboxylic acid ethyl
   ester solution and antimony trichloride powder, raised the temperature of the solution,
   reacted, added potassium chloride solution, lay up, got crystal, filter, washed with the
   sodium nitrate solution for several times, washed with the 2,6-dimethyl pyridine
   solution for several times, washed with the difluorodichloromethane solution for
15 several times, re-crystallized in the diethylene glycol ether solution, dehydrated with
   dehydration, got the finished product 11 -ketone- 16a, 17a-epoxy progesterone.

                                                   1
          Pharmaceutical      hormone      intermediates       11-ketone-16a,     17a-epoxy
   progesterone synthesis method
          FIELD OF THE INVENTION
 5        The present invention relates to a method for preparing a pharmaceutical
   intermediate which belongs to the field of organic synthesis, more particularly, relates
   to pharmaceutical hormone intermediates 11-ketone-16a, 17a-epoxy progesterone
   synthesis method.
10        GENERAL BACKGROUND
          11-ketone-16a, 17a-epoxy progesterone is a kind of pharmaceutical hormone
   intermediates. It is used for the production of cortisone, cortisone acetate which has the
   anti-inflammatory agent function is the intermediate of prednisone acetate, and it is
   mainly used to treat the adrenal cortical dysfunction, rheumatoid arthritis, rheumatism,
15 lupus erythematosus and other diseases. However, most of the existing synthesis
   methods are using the chromium oxide, manganese chloride and acetic acid as reactants.
   Because of chromium oxide and manganese pollutes environment heavily, the reaction
   process does not meet the requirements of environmental protection, the pollution
   treatment is of higher physical cost, and the synthesis method is complicated. Therefore,
20 it is necessary to propose a new synthesis method.
          SUMMARY
          Based on the technical problems of the background technology, the purpose of the
   present invention is to provide pharmaceutical hormone intermediates 11-ketone-16a,
25 17a-epoxy progesterone synthesis method, comprises the following steps:
          A:  2-bromine-1 1a-hydroxy- 14-amino- 16 a, 17a-epoxy progesterone,          1.8  L
   sodium sulfate solution were added to the reaction vessel, controlled the stirring speed
   at 150-170rpm, controlled the temperature of the solution to 10-16'C, reacted for 50-70
   min;
30
          B: added furan carboxylic acid ethyl ester solution and antimony trichloride

                                                   2
   powder, raised the temperature of the solution to 30-35 0 C, reacted for 1-2h, added 2 L
   potassium chloride solution, lay up for 2-3h, got crystal, filter, washed with the sodium
   nitrate solution for several times, washed with the 2,6-dimethyl pyridine solution for
   several times, washed with the difluorodichloromethane solution for several times,
 5
   re-crystallized in the diethylene glycol ether solution, dehydrated with dehydration, got
   the finished product 11 -ketone- 16a, 17a-epoxy progesterone.
         Preferably, the sodium sulfate solution has a mass fraction of 15-22%.
         Preferably, the mass fraction of the furan carboxylic acid ethyl ester solution is
   20-25%.
10       Preferably, the potassium chloride solution has a mass fraction of 10-17%.
         Preferably, the sodium nitrate solution has a mass fraction of 20-26%.
         Preferably, the mass fraction of 2, 6-dimethyl pyridine solution is 50-57%.
         Preferably, the difluorodichloromethane solution has a mass fraction of 55-62%.
         Preferably, the mass fraction of diethylene glycol ether solution is 80-86%.
15       Throughout the reaction process can be the following reaction formula:
                                              0                                           0
                                                                                           \C--CH2
                          NH2     C..-CH
                  HO                                                                           0
                                       + C7Hs0 3 + CISb
         Compared with the synthetic method disclosed in the background art, the
   invention provides pharmaceutical hormone intermediates 1 I-ketone- 16a, 17a-epoxy
   progesterone synthesis method, it is unnecessary to use chromium oxide, manganese
20 chloride and acetic acid as reactants, avoiding the environmental pollution of chromium
   oxide and manganese chloride and the reaction process meets the requirements of
   environmental protection, reducing pollution treatment cost, reducing intermediate
   links reaction, decreasing the reaction time and improving the reaction yield, at the
   same time, the present invention provides a new synthetic route which has laid a good
25 foundation for further enhancing the yield of the reaction.
         DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
         The following examples with reference to specific embodiments of the present

                                                 3
   invention are further illustrated:
         Embodiment 1
         Pharmaceutical hormone intermediates 11-ketone-16aiu, 17a-epoxy progesterone
   synthesis method, comprises the following steps:
 5       A: 2 mol 2-bromine-11a-hydroxy-14-amino-16u, 17a-epoxy progesterone, 1.8 L
   sodium sulfate solution with a mass fraction of 15%were added to the reaction vessel,
   controlled the stirring speed at 150rpm, controlled the temperature of the solution to
   100 C, react for 50min;
         B: added 4 mol furan carboxylic acid ethyl ester solution with a mass fraction of
10 20% and 2 mol antimony trichloride powder, raised the temperature of the solution to
   30'C, reacted for lh, added 2 L potassium chloride solution with a mass fraction of 10%,
   lay up for 2h,got crystal, filter, washed with the sodium nitrate solution with a mass
   fraction of 20% for two times, washed with the 2,6-dimethyl pyridine solution with a
   mass fraction of 50% for four times, washed with the difluorodichloromethane solution
15 with a mass fraction of 55% for three times, re-crystallized in the diethylene glycol
   ether solution with a mass fraction of 80%, dehydrated with anhydrous magnesium
   sulfate dehydration, got the finished product 11-ketone-16a, 17a-epoxy progesterone
   673.74g, yield of 98.5%.
         Embodiment 2
20       Pharmaceutical hormone intermediates 11 -ketone- 16a, 17a-epoxy progesterone
   synthesis method, comprises the following steps:
         A: 2 mol 2-bromine-1 1a-hydroxy- 14-amino-I 6u, 17a-epoxy progesterone, 1.8 L
   sodium sulfate solution with a mass fraction of 17%were added to the reaction vessel,
   controlled the stirring speed at 160rpm, controlled the temperature of the solution to
25 14C, react for 60min;
         B: added 5 mol furan carboxylic acid ethyl ester solution with a mass fraction of
   23% and 2.5 mol antimony trichloride powder, raised the temperature of the solution to
   34'C, reacted for 1.5h, added 2 L potassium chloride solution with a mass fraction of
   15%, lay up for 2.5h,got crystal, filter, washed with the sodium nitrate solution with a
30 mass fraction of 24% for three times, washed with the 2,6-dimethyl pyridine solution

                                                  4
   with a mass fraction of 55% for five times, washed with the difluorodichloromethane
   solution with a mass fraction of 59% for four times, re-crystallized in the diethylene
   glycol ether solution with a mass fraction of 85%, dehydrated with activated alumina
   dehydration,   got the finished product 11-ketone-16a,          17a-epoxy progesterone
 5 1017.792g, yield of 99.2%.
         Embodiment 3
         Pharmaceutical hormone intermediates 11-ketone-16a, 17a-epoxy progesterone
   synthesis method, comprises the following steps:
         A: 2 mol 2-bromine-1 1a-hydroxy- 14-amino-1 6a, 17a-epoxy progesterone, 1.8 L
10 sodium sulfate solution with a mass fraction of 22%were added to the reaction vessel,
   controlled the stirring speed at 170rpm, controlled the temperature of the solution to
   16'C, react for 70min;
         B: added 6 mol furan carboxylic acid ethyl ester solution with a mass fraction of
   25% and 3 mol antimony trichloride powder, raised the temperature of the solution to
15 35 C, reacted for 2h, added 2 L potassium chloride solution with a mass fraction of 17%,
   lay up for 3h,got crystal, filter, washed with the sodium nitrate solution with a mass
   fraction of 26% for four times, washed with the 2,6-dimethyl pyridine solution with a
   mass fraction of 57% for six times, washed with the difluorodichloromethane solution
   with a mass fraction of 62% for five times, re-crystallized in the diethylene glycol ether
20 solution with a mass fraction of 86%, dehydrated with anhydrous calcium chloride
   dehydration,   got the finished product I 1-ketone- 16a., 17a-epoxy progesterone
   1021.896g, yield of 99.6%.
          The embodiments of the present invention are merely preferred embodiments of
   the present invention, but the range of the present invention is not limited this, and
25 any person who is familiar with those skilled in the arts, within the technical range of
   the present invention. It is intended that the technical solution and its inventive
   concept be replaced or modified equivalently with reference to the range of the
   invention.

                                                   5
        Claims
         1.   Pharmaceutical     hormone      intermediates   11 -ketone- 16a,   17a-epoxy
   progesterone synthesis method, comprises the following steps:
 5      A: 2-bromine-11 a -hydroxy-14-amino-16a,          17a-epoxy progesterone,     1.8 L
   sodium sulfate solution were added to the reaction vessel, controlled the stirring speed
   at 150-170rpm, controlled the temperature of the solution to 10-16'C, reacted for
   50-70 min;
        B: added furan carboxylic acid ethyl ester solution and antimony trichloride
10
   powder, raised the temperature of the solution to 30-35"C, reacted for 1-2h, added 2 L
   potassium chloride solution, lay up for 2-3h, got crystal, filter, washed with the
   sodium nitrate solution for several times, washed with the 2,6-dimethyl pyridine
   solution for several times, washed with the difluorodichloromethane solution for
   several times, re-crystallized in the diethylene glycol ether solution, dehydrated with
15
   dehydration, got the finished product 11 -ketone- 16a, 17a-epoxy progesterone.
        2.    Pharmaceutical     hormone      intermediates   11 -ketone- I 6a,  17a-epoxy
   progesterone synthesis method according to claim 1 wherein the sodium sulfate
   solution has a mass fraction of 15-22%.
        3.    Pharmaceutical     hormone      intermediates   11 -ketone- 16a,   17a-epoxy
20 progesterone synthesis method according to claim 1 wherein the mass fraction of the
   furan carboxylic acid ethyl ester solution is 20-25%.
        4.    Pharmaceutical     hormone      intermediates   11 -ketone- 16a,   17a-epoxy
   progesterone synthesis method according to claim 1 wherein the potassium chloride
   solution has a mass fraction of 10-17%.

